Clinical studies with drugs and biologics aimed at slowing or reversing normal aging processes—emerging results and future perspectives
Five families of investigational products are in clinical investigation to slow or reverse normal aging processes [longevity candidates, mesenchymal stem cells, senolytics drugs, sirtuin activators, and nicotinamide adenine dinucleotide (NAD)+ precursors]. The longevity candidates, vitamin D and met...
Saved in:
Main Author: | Ricardo P. Garay |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration
2024-04-01
|
Series: | Exploration of Drug Science |
Subjects: | |
Online Access: | https://www.explorationpub.com/uploads/Article/A100840/100840.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Frailty in older adults admitted to hospital: outcomes from the Western Sydney Clinical Frailty Registry
by: Julee McDonagh, et al.
Published: (2025-02-01) -
The Intersection of Epigenetics and Senolytics in Mechanisms of Aging and Therapeutic Approaches
by: Daiana Burdusel, et al.
Published: (2024-12-01) -
Advances in regenerative medicine-based approaches for skin regeneration and rejuvenation
by: Nathalia Silva Dutra Alves, et al.
Published: (2025-02-01) -
Genetics of aging and longevity
by: A. A. Moskalev, et al.
Published: (2016-09-01) -
Genetic status assessment and future development forecast for an isolated giant panda population
by: Jiabin Liu, et al.
Published: (2025-01-01)